CANF logo

Can-Fite BioPharma (CANF) EBITDA

Annual EBITDA

-$8.18 M
+$1.90 M+18.87%

December 31, 2023

Summary

Performance

1-Year Change

+18.87%

3-Year Change

+42.1%

5-Year Change

-33.53%

15-Year Change

-28.11%

CANF EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

65.88%
CANF annual EBITDA is higher than 65.88% of companies in Healthcare sector

High & Low

All-time High

-$3.53 M

3-Year Low

-$12.83 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
CANF previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Mar 28, 2025
CANF next annual earnings announcement is scheduled for Mar 28, 2025

OtherCANFprofitabilitymetrics:

Annual Revenue

$743.00 K
CANF annual revenue is $743.00 thousand

Annual Net Income

-$7.63 M
CANF annual net profit is -$7.63 million

Annual EBIT

-$8.20 M
CANF annual earnings before interest & taxes is -$8.20 million

Annual EPS

-$3.00
CANF annual earnings per share is -$3.00

Quarterly EBITDA

N/A

June 30, 2024

Summary

Performance

3-Month Change

-

1-Year Change

-

3-Year Change

-

5-Year Change

-

CANF Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$95.00 K
CANF quarterly EBITDA is currently at an all-time high

3-Year Low

-$4.03 M
CANF quarterly EBITDA is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Jun 30, 2024
CANF previous earnings announcement was published on Jun 30, 2024

Next Quarterly Earnings Report Date

Mar 28, 2025
CANF next earnings announcement is scheduled for Mar 28, 2025

OtherCANFprofitabilitymetrics:

Quarterly Revenue

-
CANF quarterly revenue value is unknown

Quarterly Net Income

-
CANF quarterly net profit value is unknown

Quarterly EBIT

-
CANF quarterly earnings before interest & taxes value is unknown

Quarterly EPS

-
CANF quarterly earnings per share value is unknown

TTM EBITDA

N/A

June 30, 2024

Summary

Performance

3-Month Change

-

1-Year Change

-

3-Year Change

-

5-Year Change

-

CANF TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$872.70 K
CANF TTM EBITDA is currently at an all-time high

3-Year Low

-$13.04 M
CANF TTM EBITDA is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Jun 30, 2024
CANF previous earnings announcement was published on Jun 30, 2024

Next Quarterly Earnings Report Date

Mar 28, 2025
CANF next earnings announcement is scheduled for Mar 28, 2025

OtherCANFprofitabilitymetrics:

TTM Revenue

-
CANF TTM revenue value is unknown

TTM Net Income

-
CANF TTM net profit value is unknown

TTM EBIT

-
CANF TTM earnings before interest & taxes value is unknown

TTM EPS

-
CANF TTM earnings per share value is unknown

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

-$8.18 M
CANF annual EBITDA is -$8.18 million

Annual Net Income

-$7.63 M
CANF annual net profit is -$7.63 million

Annual Interest Expense

-
CANF annual interest expense value is unknown

Annual Income Tax

$0.00
CANF annual income tax is $0.00

Annual D&A

$15.00 K
CANF annual depreciation & amortization is $15.00 thousand

CANF EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+18.9%--
3 y3 years+42.1%--
5 y5 years-33.5%--

CANF EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+36.2%
5 y5-yearat high+42.1%
alltimeall time-132.0%+42.1%

Can-Fite BioPharma EBITDA History

DateAnnualQuarterlyTTM
Dec 2023
-$8.18 M(-18.9%)
-$1.83 M(-1.7%)
-$8.20 M(-13.2%)
Sep 2023
-
-$1.86 M(+4.5%)
-$9.44 M(-7.0%)
Jun 2023
-
-$1.78 M(-34.2%)
-$10.15 M(-2.7%)
Mar 2023
-
-$2.71 M(-12.0%)
-$10.44 M(+3.4%)
Dec 2022
-$10.08 M(-21.4%)
-$3.08 M(+19.8%)
-$10.10 M(-8.6%)
Sep 2022
-
-$2.57 M(+24.3%)
-$11.04 M(-7.8%)
Jun 2022
-
-$2.07 M(-12.7%)
-$11.98 M(-8.2%)
Mar 2022
-
-$2.37 M(-41.2%)
-$13.04 M(+1.5%)
Dec 2021
-$12.83 M(-9.2%)
-$4.03 M(+14.8%)
-$12.84 M(+3.8%)
Sep 2021
-
-$3.51 M(+12.0%)
-$12.37 M(+9.1%)
Jun 2021
-
-$3.13 M(+44.3%)
-$11.34 M(-5.8%)
Mar 2021
-
-$2.17 M(-38.9%)
-$12.03 M(-14.9%)
Dec 2020
-$14.13 M(+17.8%)
-$3.55 M(+43.3%)
-$14.14 M(-7.0%)
Sep 2020
-
-$2.48 M(-35.3%)
-$15.20 M(-2.0%)
Jun 2020
-
-$3.83 M(-10.4%)
-$15.51 M(+6.4%)
Mar 2020
-
-$4.28 M(-7.3%)
-$14.58 M(+21.4%)
Dec 2019
-$11.99 M(+95.8%)
-
-
Dec 2019
-
-$4.61 M(+65.2%)
-$12.01 M(+10.9%)
Sep 2019
-
-$2.79 M(-3.9%)
-$10.82 M(+33.2%)
Jun 2019
-
-$2.90 M(+70.6%)
-$8.13 M(+29.8%)
Mar 2019
-
-$1.70 M(-50.3%)
-$6.26 M(+2.0%)
Dec 2018
-$6.13 M(-4.1%)
-
-
Dec 2018
-
-$3.43 M(+3506.3%)
-$6.14 M(+31.0%)
Sep 2018
-
-$95.00 K(-90.8%)
-$4.69 M(-19.4%)
Jun 2018
-
-$1.04 M(-34.5%)
-$5.81 M(-7.4%)
Mar 2018
-
-$1.58 M(-19.8%)
-$6.28 M(-2.0%)
Dec 2017
-$6.38 M(-23.5%)
-
-
Dec 2017
-
-$1.97 M(+61.4%)
-$6.40 M(-19.6%)
Sep 2017
-
-$1.22 M(-18.6%)
-$7.96 M(-9.3%)
Jun 2017
-
-$1.50 M(-12.1%)
-$8.78 M(-1.6%)
Mar 2017
-
-$1.71 M
-$8.92 M
DateAnnualQuarterlyTTM
Dec 2016
-$8.35 M(+30.4%)
-
-
Dec 2016
-
-$3.53 M(+73.1%)
-$8.36 M(+15.2%)
Sep 2016
-
-$2.04 M(+24.1%)
-$7.26 M(-0.3%)
Jun 2016
-
-$1.64 M(+42.9%)
-$7.29 M(+1.4%)
Mar 2016
-
-$1.15 M(-52.6%)
-$7.19 M(+12.1%)
Dec 2015
-$6.40 M(+2.1%)
-
-
Dec 2015
-
-$2.43 M(+17.6%)
-$6.42 M(+10.2%)
Sep 2015
-
-$2.07 M(+33.6%)
-$5.82 M(+20.6%)
Jun 2015
-
-$1.55 M(+311.0%)
-$4.83 M(-0.9%)
Mar 2015
-
-$376.10 K(-79.5%)
-$4.87 M(-22.4%)
Dec 2014
-$6.27 M(-26.9%)
-
-
Dec 2014
-
-$1.83 M(+71.3%)
-$6.28 M(-17.9%)
Sep 2014
-
-$1.07 M(-32.6%)
-$7.64 M(-4.6%)
Jun 2014
-
-$1.59 M(-10.8%)
-$8.02 M(-1.5%)
Mar 2014
-
-$1.78 M(-44.3%)
-$8.14 M(+1.2%)
Dec 2013
-$8.57 M(+46.9%)
-$3.20 M(+122.0%)
-$8.04 M(+16.4%)
Sep 2013
-
-$1.44 M(-15.9%)
-$6.91 M(+4.3%)
Jun 2013
-
-$1.71 M(+1.9%)
-$6.62 M(+8.5%)
Mar 2013
-
-$1.68 M(-18.7%)
-$6.10 M(+2.4%)
Dec 2012
-$5.84 M(-20.4%)
-
-
Dec 2012
-
-$2.07 M(+79.2%)
-$5.96 M(-22.1%)
Sep 2012
-
-$1.16 M(-3.2%)
-$7.65 M(+1.5%)
Jun 2012
-
-$1.19 M(-22.4%)
-$7.53 M(+0.0%)
Mar 2012
-
-$1.54 M(-59.1%)
-$7.53 M(+2.2%)
Dec 2011
-$7.33 M(+108.0%)
-
-
Dec 2011
-
-$3.76 M(+261.9%)
-$7.37 M(+62.0%)
Sep 2011
-
-$1.04 M(-12.8%)
-$4.55 M(+3.8%)
Jun 2011
-
-$1.19 M(-13.4%)
-$4.38 M(+37.4%)
Mar 2011
-
-$1.38 M(+46.4%)
-$3.19 M(+75.9%)
Dec 2010
-$3.53 M
-
-
Dec 2010
-
-$940.40 K(+7.8%)
-$1.81 M(+107.8%)
Sep 2010
-
-$872.70 K
-$872.70 K

FAQ

  • What is Can-Fite BioPharma annual EBITDA?
  • What is the all time high annual EBITDA for Can-Fite BioPharma?
  • What is Can-Fite BioPharma annual EBITDA year-on-year change?
  • What is the all time high quarterly EBITDA for Can-Fite BioPharma?
  • What is the all time high TTM EBITDA for Can-Fite BioPharma?

What is Can-Fite BioPharma annual EBITDA?

The current annual EBITDA of CANF is -$8.18 M

What is the all time high annual EBITDA for Can-Fite BioPharma?

Can-Fite BioPharma all-time high annual EBITDA is -$3.53 M

What is Can-Fite BioPharma annual EBITDA year-on-year change?

Over the past year, CANF annual EBITDA has changed by +$1.90 M (+18.87%)

What is the all time high quarterly EBITDA for Can-Fite BioPharma?

Can-Fite BioPharma all-time high quarterly EBITDA is -$95.00 K

What is the all time high TTM EBITDA for Can-Fite BioPharma?

Can-Fite BioPharma all-time high TTM EBITDA is -$872.70 K